MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	SLABÝ Ondřej LAKOMÝ Roman FADRUS Pavel HRSTKA Roman KŘEN Leoš LŽIČAŘOVÁ Eva SMRČKA Martin SVOBODA Marek DOLEŽALOVÁ H. NOVÁKOVÁ Jana VALÍK Dalibor VYZULA Rostislav MICHÁLEK Jaroslav
Year of publication	2010
Type	Article in Periodical
Magazine / Source	Neoplasma
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.4149/neo_2010_03_264
Field	Microbiology, virology
Keywords	microRNA; MGMT methylation; glioblastoma; chemoradiotherapy; temozolomide
Description	MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0,016), miR-222 (p=0,038), miR-181b (p=0,036), miR-181c (p=0,043) and miR-128a (p=0,001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0,001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0,016; p=0,047, respectively) in comparison to patients with progredient disease. Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients.